198 related articles for article (PubMed ID: 36128328)
21. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
Okazaki A; Gameiro PA; Christodoulou D; Laviollette L; Schneider M; Chaves F; Stemmer-Rachamimov A; Yazinski SA; Lee R; Stephanopoulos G; Zou L; Iliopoulos O
J Clin Invest; 2017 May; 127(5):1631-1645. PubMed ID: 28346230
[TBL] [Abstract][Full Text] [Related]
22. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
Rathkey D; Khanal M; Murai J; Zhang J; Sengupta M; Jiang Q; Morrow B; Evans CN; Chari R; Fetsch P; Chung HJ; Xi L; Roth M; Filie A; Raffeld M; Thomas A; Pommier Y; Hassan R
J Thorac Oncol; 2020 May; 15(5):843-859. PubMed ID: 32004714
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Tentori L; Muzi A; Dorio AS; Scarsella M; Leonetti C; Shah GM; Xu W; Camaioni E; Gold B; Pellicciari R; Dantzer F; Zhang J; Graziani G
Curr Cancer Drug Targets; 2010 Jun; 10(4):368-83. PubMed ID: 20464779
[TBL] [Abstract][Full Text] [Related]
25. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
[TBL] [Abstract][Full Text] [Related]
26. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.
Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
[TBL] [Abstract][Full Text] [Related]
27. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
28. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
[TBL] [Abstract][Full Text] [Related]
29. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
[TBL] [Abstract][Full Text] [Related]
30. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
32. Succinate dehydrogenase B-deficient renal cell carcinoma: A case report with novel germline mutation.
Iwashita H; Okudela K; Matsumura M; Yamanaka S; Sawazumi T; Enaka M; Udaka N; Miyake A; Hibiya T; Miyake N; Matsumoto N; Makiyama K; Yao M; Nagashima Y; Ohashi K
Pathol Int; 2017 Nov; 67(11):585-589. PubMed ID: 28960644
[TBL] [Abstract][Full Text] [Related]
33. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ
J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274
[TBL] [Abstract][Full Text] [Related]
34. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
35. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings.
Lendvai N; Pawlosky R; Bullova P; Eisenhofer G; Patocs A; Veech RL; Pacak K
Endocrinology; 2014 Jan; 155(1):27-32. PubMed ID: 24189137
[TBL] [Abstract][Full Text] [Related]
36. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
[TBL] [Abstract][Full Text] [Related]
37. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
38. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase.
Pollard PJ; Wortham NC; Tomlinson IP
Ann Med; 2003; 35(8):632-9. PubMed ID: 14708972
[TBL] [Abstract][Full Text] [Related]
39. Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female.
Wyvekens N; Anderson WJ; Kim YX; Carter M; Hirsch MS
Int J Surg Pathol; 2022 Apr; 30(2):184-189. PubMed ID: 34180725
[TBL] [Abstract][Full Text] [Related]
40. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]